Analyst Price Targets — VCEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2026 5:07 pm | Caitlin Cronin | Canaccord Genuity | $60.00 | $47.93 | StreetInsider | Vericel Corporation (VCEL) PT Raised to $60 at Canaccord |
| July 16, 2026 2:08 pm | Richard Newitter | Truist Financial | $54.00 | $47.88 | TheFly | Vericel price target raised to $54 from $42 at Truist |
| May 8, 2026 10:17 am | — | H.C. Wainwright | $70.00 | $35.13 | TheFly | Vericel price target raised to $70 from $64 at H.C. Wainwright |
| April 15, 2026 12:45 pm | — | Truist Financial | $42.00 | $35.21 | TheFly | Vericel price target lowered to $42 from $48 at Truist |
| March 10, 2026 7:55 pm | Mike Kratky | Leerink Partners | $46.00 | $33.40 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vericel Corporation (VCEL) following conference |
| December 18, 2025 2:16 pm | Richard Newitter | Truist Financial | $45.00 | $36.42 | TheFly | Vericel price target lowered to $45 from $50 at Truist |
| October 15, 2025 12:48 pm | — | Truist Financial | $41.00 | $34.50 | TheFly | Vericel price target lowered to $41 from $46 at Truist |
| December 18, 2024 12:32 pm | Richard Newitter | Truist Financial | $67.00 | $56.25 | TheFly | Vericel price target raised to $67 from $61 at Truist |
| August 26, 2024 9:33 am | Ryan Zimmerman | BTIG | $55.00 | $50.05 | StreetInsider | BTIG Reiterates Buy Rating on Vericel Corporation (VCEL) |
| August 2, 2024 6:07 am | Swayampakula Ramakanth | H.C. Wainwright | $60.00 | $47.52 | TheFly | Vericel price target raised to $60 from $55 at H.C. Wainwright |
Latest News for VCEL
Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in…
Allspring Global Investments Holdings LLC trimmed its position in Vericel Corporation (NASDAQ: VCEL) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 678,003 shares of the biotechnology company's stock after selling 21,710 shares during the quarter. Allspring Global Investments Holdings
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCEL.
U.S. House Trading
No House trades found for VCEL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.